Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.

Jason J SchaferMatty ZimmermanCiara WalsheJesse CerankowskiAyako ShimadaScott W Keith

Published in: Obesity (Silver Spring, Md.) (2022)

Despite observing significant unadjusted metabolic changes after switching to TAF, only changes in cholesterol were associated with TAF and were different from changes expected in time-trend adjusted models.

Keyphrases

antiretroviral therapy
sars cov
body mass index
weight loss
physical activity
low density lipoprotein
weight gain